Engineered proteins for drug delivery
Wouter Verdurmen’s research group focuses on designing and investigating engineered proteins that overcome delivery barriers, employing synthetic binding proteins for target recognition. Various (super-resolution) microscopy techniques as well as microfluidic tumor-on-a-chip approaches are used.
Sander Leeuwenburgh's research group focuses on developing advanced tissue regenerative therapies, utilizing biomaterials either or not combined with biological components. These therapies exploit biomaterial properties, patient-derived cells or therapeutic molecules to empower their functionality.
Renal electrolyte handling
René Bindels' research group studies the regulation of ion transport processes in kidney and small intestine in health and disease. Current projects involve the molecular mechanisms underlying rare tubulopathies and the regulation of the newly identified calcium, magnesium and sodium transporters.
Roland Brock’s group focuses on the targeted delivery of molecules such as oligonucleotides, toxins and photosensitizers to modulate cell function and/or induce cell death. This research involves fundamental studies of formulation strategies and uptake mechanisms as well as preclinical applications.
William Leenders' group performs targeted quantitative next generation sequencing of RNA from surgery-derived cancer tissues in retrospective studies, tries to translate the findings into personalized precision therapy with available cancer treatments, and develops innovative targeted nanomedicines.
Joost Hoenderop's group focuses on tubular transport of calcium, magnesium and sodium by the kidney tubule and the changes therein. For acquired renal disorders, uncovering the underlying mechanism, prevention and rational treatments for drug-induced toxicities is a main focus.